Trials / Terminated
TerminatedNCT00206089
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
The "EXTEND" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,300 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EXANTA |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-09-21
- Last updated
- 2010-11-15
Locations
125 sites across 16 countries: Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Mexico, Netherlands, Norway, Poland, Portugal, South Africa, Spain, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT00206089. Inclusion in this directory is not an endorsement.